Boehringer Ingelheim has launched a Phase II trial of BI 3034701, a first-in-class GLP-1/GIP/NPY2 receptor agonist, evaluating its safety, efficacy, and optimal dosing in adults with obesity and overweight.
Written By: Meghana Jinka, PharmD
Reviewed By: Pharmacally Editorial Team
Boehringer Ingelheim has initiated a Phase II clinical trial (NCT07662122) evaluating BI 3034701, a novel triple GLP-1/GIP/NPY2 receptor agonist, in adults living with obesity and overweight. The study marks the first mid-stage clinical evaluation of the investigational therapy and represents an important step in the company’s strategy to develop differentiated treatments for obesity and related cardiometabolic diseases.
The Phase II trial will assess dose selection alongside the efficacy and safety of BI 3034701 in people with obesity and overweight. The program builds on encouraging Phase I findings, in which the investigational therapy demonstrated a generally favorable safety and tolerability profile.
Scientific and Clinical Context
Obesity affects more than one billion people worldwide and substantially increases the risk of cardiovascular disease, chronic kidney disease, type 2 diabetes, and other metabolic disorders. Despite the success of GLP-1-based therapies, obesity remains a heterogeneous disease, highlighting the need for treatments that target multiple biological pathways and address varying patient needs.
BI 3034701 combines three complementary mechanisms in a single molecule. It activates the glucagon-like peptide-1 (GLP-1) receptor and glucose-dependent insulinotropic polypeptide (GIP) receptor, which are known to promote satiety, weight loss, and metabolic regulation. The candidate also activates the neuropeptide Y2 (NPY2) receptor, an emerging therapeutic target believed to regulate central hunger signaling and appetite control. Although the clinical contribution of NPY2 receptor activation continues to be investigated, the approach could provide a differentiated strategy beyond currently available incretin therapies.
The investigational therapy originated through a collaboration with Gubra, while Boehringer Ingelheim is responsible for its ongoing clinical development and global commercialization.
Phase II Trial Details
The Phase II study will enroll adults with obesity and overweight to evaluate the efficacy, safety, and optimal dosing of BI 3034701. While detailed study endpoints have not yet been disclosed, the trial is expected to generate key clinical data supporting dose selection for later-stage development.
Advancement into Phase II follows Phase I studies demonstrating a generally favorable safety and tolerability profile, supporting continued clinical evaluation of the triple agonist.
Clinical Perspective
Dr. Ania Jastreboff, Professor at Yale School of Medicine and Director of the Yale Obesity Research Center (Y-Weight), said the expanding obesity treatment landscape requires therapies that target diverse biological mechanisms because obesity presents differently across patient populations. She noted that broader therapeutic options could help clinicians better match treatments to individual patients based on disease characteristics and risk profiles.
Shashank Deshpande, Chairman of the Board of Managing Directors and Head of Human Pharma at Boehringer Ingelheim, said the company aims to advance earlier, multi-pathway interventions that improve long-term cardiometabolic outcomes. He added that future obesity care is expected to become increasingly personalized, with therapies addressing both the biological and behavioral drivers of the disease.
Path Forward
BI 3034701 expands Boehringer Ingelheim’s growing obesity and metabolic disease pipeline. The portfolio also includes survodutide, a dual glucagon/GLP-1 receptor agonist currently in Phase III development, with recent data presented at the American Diabetes Association Scientific Sessions 2026. The company is also advancing additional next-generation injectable and oral therapies targeting obesity, liver disease, and broader cardiometabolic disorders.
If Phase II results confirm the candidate’s safety and clinical activity, BI 3034701 could emerge as a first-in-class triple receptor agonist and provide a differentiated treatment option for patients living with obesity and overweight.
Reference
Obesity potential first-in-class triple receptor agonist Phase 2 | Boehringer Ingelheim
About the Writer
Meghana Jinka (LinkedIn) is a Pharm.D graduate with a strong interest in clinical pharmacy, clinical research, pharmacovigilance, and medical writing. She has developed expertise in evaluating scientific literature, interpreting clinical data, and communicating complex medical information in a clear and accessible manner. Through clinical training, patient counseling, and healthcare awareness activities, she has gained practical experience in evidence-based medicine and patient-centered care. Passionate about healthcare communication, Meghana is committed to developing accurate, engaging, and evidence-based healthcare documents that support healthcare professionals and the wider community.